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Abstract
p21 Ras proteins play a critical role in the regulation of cellular growth and differentiation. In addition, Ras and proteins
which regulate Ras activity have been implicated in long-term memory consolidation and long-term potentiation processes.
Over the last few years, much evidence has emerged which indicates that changes in cytoplasmic Ca2 levels can regulate Ras
protein activity and subsequent biological function. Also, Ras proteins themselves can modulate intracellular Ca2 levels by
regulating both Ca2 release and Ca2 influx processes. Here we examine the signalling components which regulate Ras
activity and, in particular, consider points of convergence between intracellular Ca2 and p21 Ras signalling processes. In
addition, we consider the possible biological consequences resulting from the integration of these signalling pathways and
highlight the importance of our understanding protein^protein interactions. Finally, we discuss the possibility of protein^
protein interactions mediated via Ca2-responsive structural domains, such as the C2 and IQ domains, playing important
roles in Ca2-dependent Ras functions yet to be established. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Over the last few years our knowledge concerning
the Ras signalling pathway has been expanding at an
ever increasing rate. As a result of great advances
which have been made in the detection of protein^
protein interactions and the identi¢cation of multiple
structural domains located within key Ras pathway
proteins, a much better understanding of how signals
are transmitted and a greater appreciation of the
complexity of signalling networks has been gained.
Here we shall consider the ways in which p21 Ras
activity is regulated and in particular the role played
by protein^protein interactions will be highlighted.
We shall examine how tyrosine kinase and G-pro-
tein-coupled receptors activate Ras and how these
receptor-mediated pathways also often lead to the
elevation of intracellular Ca2. Finally, we shall con-
sider the evidence that Ras plays a role in the regu-
lation of intracellular Ca2 levels and discuss how
Ca2 and Ras signalling pathway integration may
lead to our further understanding of a role for Ras
in brain function.
2. Ras proteins
p21 Ras proteins are 21 kDa guanine nucleotide
binding proteins which are encoded by three cellular
genes; H-ras, K-ras and N-ras [1]. They are located
at the inner surface of the plasma membrane as a
result of lipophilic interactions mediated via a poly-
isoprenylated C-terminus [2]. When the post-transla-
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tional modi¢cation of this C-terminus is blocked,
Ras proteins are unable to membrane associate and
consequently lose their biological activity [3].Exami-
nation of the primary structure of H-, K-, and N-Ras
proteins reveals that they are highly homologous in
their ¢rst 164 amino acids, with the ¢rst 86 amino
acids being identical and the following 78 residues
displaying 79% identity [4]. Intriguingly, amino acids
165^185 are highly divergent, possibly indicating dis-
tinct cellular function. However, what these selective
functions may be have not been discovered since the
deletion of this region does not appear to disrupt the
structural integrity or the biological function of Ras
proteins [5].
The crystal structure of Ras proteins has been
solved and, in common with other guanine nucleotide
binding proteins, a GTP binding site and a GTP hy-
drolysing (GTPase) domain have been located [6].
Two ‘switch’ regions have been proposed which ex-
hibit di¡erent conformations depending upon the
binding of GTP or GDP to the protein. One of these
switch regions located between amino acid residues
30^40 contains the e¡ector binding site (the ‘e¡ector
domain’). It is to this region that e¡ectors (proteins
transmitting downstream signalling events) such as
raf 1 kinase and phosphatidylinositol 3-kinase, and
the GTPase activating protein p120GAP, bind when
Ras proteins are in the GTP bound conformation
[7]. In this way, the biological activity of Ras proteins
is dependent upon the guanine nucleotide bound
state. When in the GTP bound state, the protein is
functionally active and conversely when in the GDP
bound state, the protein is functionally inactive. Tight
regulation of the guanine nucleotide bound state is
critical for the regulation of normal cellular prolifer-
ation and di¡erentiation because constitutively active
(GTP bound) Ras proteins can induce cellular trans-
formation [8]. Approximately 10% of all human tu-
mours, 70% of pancreatic and 50% of colorectal can-
cers are associated with mutation of Ras genes
resulting in a constitutively activated protein [9].
3. Regulation of Ras proteins
Ras proteins are regulated by two major classes of
proteins: guanine nucleotide exchange factors
(GEFs) and GTPase activating proteins (GAPs).
GEFs are also known as guanine nucleotide release
factors (GRFs) or guanine nucleotide dissociation
stimulators (GDSs). GEFs function to promote the
release of GDP and the binding of GTP to Ras pro-
teins [10]. GAPs function to stimulate the intrinsic
GTPase activity of Ras proteins so that GTP is hy-
drolysed to GDP and the G protein returns to the
inactive conformation. Ras cycles between the active
GTP and inactive GDP bound conformation, a proc-
ess known as the GTPase cycle.
3.1. GEFs: activators of Ras
Four mammalian Ras exchange factors have been
cloned. These are; SOS1, SOS2, CDC25Mm (Ras-
GRF), and GRF2 [11^15]. SOS1 and SOS2 are
mammalian homologues of the Drosophila exchange
factor Son of Sevenless (dSOS) [16]. CDC25Mm and
GRF2 are mammalian homologues of the yeast
cdc25 Ras exchange factor. SOS and the cdc25-like
GEFs represent two distinct guanine nucleotide ex-
change factor families.
Fig. 1. Diagram illustrating the structural domains of Ras exchange factors. DH, dibble homology domain; PH, pleckstrin homology
domain; IQ, ilimaquinone motif (Ca2/calmodulin binding region).
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SOS proteins have been clearly established as
being the link between tyrosine kinase/growth factor
receptor stimulation and Ras activation. SOS is ubiq-
uitously expressed and has been shown to associate
directly with a range of adaptor proteins including
Grb2, Shc, CrkII and Nck [17]. Adaptor proteins
characteristically contain no enzymatic activity, but
contain protein structural units which display se-
quence similarity with pp60Src known as Src homol-
ogy (SH) domains [18]. Growth factor receptor acti-
vation was initially proposed to promote the
movement of the SOS/Grb2 complex from a cyto-
solic to a membrane-associated cellular location
[19]. More recently, however, studies with dSOS
have demonstrated that removal of the adaptor bind-
ing region did not a¡ect the function of the protein
or its membrane localisation [20].Conversely, in
mammalian systems, Grb2/SOS interaction has
been shown to be required for the activation of
Ras by SOS [21]. Also, even though the adaptor
interaction region and the catalytic domain are lo-
cated towards the C-terminus of the protein, removal
of the dibble homology (DH) and pleckstrin homol-
ogy (PH) domains within the N-terminal region (see
Fig. 1) has been shown to result in the loss of func-
tion of the protein [20^22]. Thus, the precise trans-
location mechanism of SOS and Grb2 and the role of
the N-terminal region of SOS still needs to be re-
solved. Once SOS has stimulated the release of
GDP and the binding of GTP to Ras, the activation
of the e¡ector Raf-1 kinase and the subsequent phos-
phorylation and activation of MAPKK and MAPK
occurs (reviewed in [23]). A negative feedback mech-
anism is initiated whereby MAPK phosphorylates
the C-terminal region of SOS so that the ability of
SOS to interact with growth factor receptors is re-
duced [24].
The cdc25-like GEFs include CDC25Mm (RAS-
GRF) and GRF2 [13,15]. GRF2 displays 80% amino
acid sequence identity with p140 Ras-GRF. How-
ever, whereas Ras-GRF is predominantly expressed
in brain neurones with particular localisation to the
synaptic junction [13,25], GRF2 displays a much
wider tissue expression pro¢le [15]. The Ras-GRF
gene in mouse brain encodes for at least four protein
products with molecular weights ranging from ap-
proximately 70^140 kDa. The C-terminal amino
acids of each protein are identical and sequential
N-terminal extensions account for the larger sized
protein products [14]. Ras-GRF does not appear to
play a role in growth factor or tyrosine kinase acti-
vation of Ras [13,26,27]. Instead, it is activated by
Ca2 elevation, serum or lysophosphatidic acid
(LPA) treatment and M1 muscarinic receptor activa-
tion [26,27]. Ras-GRF does not interact with Grb2,
Shc or growth factor receptors [13,26]. Structural
analysis of Ras-GRF reveals the presence of two
PH domains, an ilimaquinone (IQ) motif, a DH do-
main and a cdc25 nucleotide exchange stimulating
catalytic domain (see Fig. 1). Unlike SOS, it does
not need to be translocated in the cell to access
Ras. Instead, it is located in the particulate fraction
of cells and this localisation appears to require the
N-terminal region of the protein [28]. Deletion of the
N-terminal PH1 domain results in the removal of the
protein from the particulate fraction. However, when
this PH domain is fused to the catalytic domain of
the protein, this construct is still unable to localise to
the membrane [28]. In addition, the PH1 domain is
required for serum activation. Since pertussis toxin
treatment inhibits serum-induced activation and PH
domains are known to bind the LQ subunits of het-
erotrimeric G proteins [29], it is feasible that serum
activation of GRF involves Gi activation and LQ sub-
unit release. Surprisingly, although GRF2 displays
high sequence homology with Ras-GRF, this ex-
change factor is not membrane-localised and requires
Ca2-elevation for its translocation to the plasma
membrane [14].
The IQ motif has been shown to bind Ca2/calm-
odulin in response to Ca2 elevation either by iono-
phore treatment or K-induced membrane depolar-
isation. Ca2/calmodulin binding results in the
stimulation of Ras-GRF exchange activity. Mutation
of the IQ motif in order to abolish calmodulin bind-
ing results in the loss of Ca2-induced activation of
Ras-GRF [25]. However, the Ca2-induced activa-
tion of Ras-GRF also requires the presence of the
PH2 and DH domains [30]. Thus, Ca2-activation of
Ras-GRF may require the Ca2-dependent binding
of calmodulin to the IQ motif and a cooperative/
allosteric e¡ect mediated by the PH and DH do-
mains. Ras-GRF has also been shown to be phos-
phorylated by Ca2/calmodulin Kinase II [30].
Although the Ras-GRF was initially cloned in an
e¡ort to isolate mammalian Ras exchange factors,
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more recently this protein has been shown to activate
not only p21 Ras proteins but also the highly related
apoptosis controlling p23 R-Ras [31]. It therefore
remains to be determined whether this GRF is a
speci¢c exchange factor for either p21 or p23 Ras
proteins or whether it can activate interchangeably
both Ras proteins, but demonstrates a selectivity in
response to cellular conditions prevailing. Function-
ally, Ras-GRF knock-out mice have been reported to
have impaired ability for memory consolidation
processes. This has led to the proposal that Ras-
GRF may play a role in long-term memory processes
[32].
3.2. GAPs: inactivators of Ras
To date, at least seven Ras selective mammalian
GAPs have been cloned [33^39]. These are; p120GAP,
GAP1m, GAP1IP4BP, GAP III, p98GAP, p135SynGAP
and neuro¢bromin. Characteristically, all GAPs con-
tain a common structural region called the GAP re-
lated domain (GRD). The GRD is the catalytic unit
of the protein which stimulates the GTPase activity
of Ras proteins. In addition to their role as Ras
regulators, GAPs have been speculated to play an
e¡ector role in Ras signalling [23]. Such speculations
have led to the investigation of the primary struc-
tures of mammalian Ras GAPs and has revealed
these proteins to contain multiple structural domains
(Fig. 2). For example, neuro¢bromin displays se-
quence similarity with the yeast Ras GAPs Ira1
and Ira2 and the Ras-related (but not Ras GTPase-
stimulating) IQGAP and expression of neuro¢bro-
min has been shown to complement yeast strains
with loss of function mutations in Ira genes [40].
However, although the Ira-like homology regions in
neuro¢bromin £ank the GAP related domain, sur-
prisingly, the expression of the neuro¢bromin GAP
related domain alone has been shown to be su⁄cient
in these complementation studies.
The mammalian p120GAP (RAS GAP) is probably
the most well studied GAP. Characteristically it con-
Fig. 2. Diagram to illustrate the structural similarities between Ras GAP members. Although all family members contain highly re-
lated catalytic domains (the GRD), p98GAP, GAP III, GAP1IP4BP and GAP1m may represent a distinct subfamily of GAPs based on
their structural similarity. SH2, Src homology region 2 domain; SH3, Src homology region 3 domain; C2, C2 domain; GRD, GAP-
related domain; PH, pleckstrin homology domain.
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tains Src homology domains (two SH2 and one SH3
domain) within its N-terminal region. Its SH2 do-
mains interact with phosphotyrosine proteins includ-
ing p62 and the Rho GAP p190, and its SH3 domain
is believed to play an e¡ector role in Ras-induced
processes [41,42]. p120GAP was the ¢rst GAP in
which a C2 domain was identi¢ed [43]. This C2 do-
main interacts with negatively charged phospholipids
[44] and may be important for the plasma membrane
association of the protein in response to intracellular
Ca2 elevation [45]. The p120GAP C2 domain also
has the ability to mediate protein^protein interac-
tions [46]. One protein which directly binds to this
C2 domain is the Ca2-dependent phospholipid bind-
ing protein annexin VI. The interaction of these pro-
teins, however, does not require the presence of
Ca2, but elevation of intracellular Ca2 results in
the co-movement of these two proteins from a cyto-
plasmic to a membrane associated cellular location
(A. Davis, A. Chow and D. Gawler, unpublished
observations).
p135 SynGAP is another GAP which has very
recently been cloned and contains one copy of a
C2 domain [39]. This Ras GAP is predominantly
found in brain where it is exclusively localised in
synapses in hippocampal neurones in a protein com-
plex with NMDA receptors. p135SynGAP is phos-
phorylated in response to Ca2 elevation by CaM
Kinase II. Phosphorylation of SynGAP reduces the
protein’s ability to stimulate Ras GTPase activity.
Due to its distribution and co-complexing with
NMDA receptors, it has been suggested that this
GAP (and therefore also Ras) may play a role in
synaptic plasticity in the brain.
p98GAP, GAP III, GAP1IP4BP and GAP1m are
structurally very similar (Fig. 2) and may therefore
constitute a subfamily of functionally related pro-
teins. Each of these GAPs contain two non-identical
C2 domains denoted C2A and C2B. When amino
acid sequence comparisons are made between C2 do-
mains in these proteins, it becomes apparent that
these A and B C2 domains form two distinct groups
since members within each group display higher se-
quence similarity to each other rather than to mem-
bers within the other group. For example, the C2A
domain within GAP III displays far greater sequence
similarity with the C2A domain within GAP1m than
it does with the C2B domain within GAP1m. In ad-
dition, sequence similarity is greater between C2 do-
mains in these GAPs than sequence similarity with
C2 domains in neurotransmitter release-related pro-
teins such as synaptotagmins or rabphilin, or surpris-
ingly the C2 domain of p120GAP. Presumably the
structure of the C2 domain must relate to its func-
tion. So what is the function of the C2 domains with-
in these GAPs?
In order to obtain clues regarding the possible
function of C2 domains one must consider the cellu-
lar functions of Ras and what is known or postulated
about C2 domains which have been studied in other
non-Ras related proteins and look for possible areas
of convergence. The best studied C2 domain contain-
ing protein is synaptotagmin. Eleven isoforms of the
protein have been cloned to date and each isoform
contains two non-identical copies of C2 domains
[47]. Eight isoforms of this protein bind higher ino-
sitol polyphosphates such as Ins(1,3,4,5)P4 and the
binding site for inositol phosphates has been mapped
to the basic (lysine rich) region of the C2B domain
[47]. However, the C-terminal region of the C2B do-
main may also play a role in regulating Ins(1,3,4,5)P4
binding in those isoforms displaying weak or no
Ins(1,3,4,5)P4 binding activity [47]. Since GAP1IP4BP
was originally puri¢ed [48] and later cloned [35] as
an Ins(1,3,4,5)P4 binding protein, it is tempting to
speculate that the C2B domain within these GAPs
may similarly function as Ins(1,3,4,5)P4 binding sites.
However, Ins(1,3,4,5)P4 binding to GAP1m has been
studied and the binding site was located not within
the C2B domain, but instead within the pleckstrin
homology (PH) domain [49]. Ins(1,3,4,5)P4 binding
to the pH domain is in£uenced by the C-terminus of
the protein and the GRD region. However, the Ras
GTPase stimulatory activity of the protein is unaf-
fected by mutations within the PH domain which
signi¢cantly a¡ected the Ins(1,3,4,5)P4 binding. This
suggests that Ins(1,3,4,5)P4 binding may be unrelated
to the GTPase stimulatory activity of the protein,
but perhaps when the protein is interacting with
Ras, then the Ins(1,3,4,5)P4 binding ability (and the
cellular consequence of this) could be regulated. The
cellular function of Ins(1,3,4,5)P4 remains controver-
sial but much evidence exists which indicates that it
plays an important role in the regulation of Ca2
channel activity [50]. Ras has also been demonstrated
to play a role in the regulation of Ca2 channels [51].
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4. Receptor activation of Ras
There are two major routes by which p21 Ras is
activated in cellular systems. The ¢rst is the most
well studied and involves the direct receptor-medi-
ated activation of tyrosine kinases. The tyrosine ki-
nase activity stimulated can either be intrinsic to the
receptor itself or can involve a two-step process
whereby the receptor activation leads to the associa-
tion and activation of a non-receptor tyrosine kinase.
The second major mechanism for activation of p21
Ras involves the activation of serpentine heterotri-
meric G-protein-coupled receptors which do not di-
rectly couple to tyrosine kinase activation, but never-
theless do subsequently require tyrosine kinase
cascades (Fig. 3).
4.1. Receptor protein tyrosine kinase (RPTK)
activation of Ras
At least 14 distinct RPTK subfamilies representing
more than 50 RPTK gene products have been iden-
ti¢ed (reviewed in [52]). Amongst the most well
studied of these receptor subfamilies are the epider-
mal growth factor receptor (EGFR), the insulin re-
ceptor (InsR), the platelet derived growth factor re-
ceptor (PDGFR) and the nerve growth factor
receptor (NGFR) subfamilies. Characteristically, all
these receptors are transmembrane proteins which
have intrinsic tyrosine kinase activity. They bind
polypeptide ligands (growth factors or cytokines) at
their N-terminal region which is exposed on the ex-
tracellular membrane surface of the cell. Binding of
ligand results in the activation of homo- or hetero-
dimerisation of receptors [53] which in turn produces
intermolecular autophosphorylation of multiple tyro-
sine residues located within the C-terminal cytoplas-
mic tail of the receptor. These tyrosine phosphoryl-
ated sites then function as docking sites for proteins
which contain SH2 domains. Some of these SH2 do-
main containing proteins display enzymatic activity
and include the proteins phospholipase C-Q (PLC-Q),
Fig. 3. Receptor activation of the Ras signalling pathway. Cartoon illustrating the mechanisms by which stimulation of growth factor
receptors (GFR) or G-protein-coupled receptors (GPCRs) lead to the activation of p21 Ras proteins.
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the p85 regulatory subunit of phosphatidylinositol-3
kinase (PI3 kinase), p120GAP and Src family kinases
[52]. However, non-enzymatic adaptor proteins in-
cluding Grb2, Shc, Crk, Nck and IRS-1 have also
been found to bind. Which proteins bind to which
receptor depends primarily on the amino acid se-
quence around the tyrosine residue which is phos-
phorylated [54]. Hence, each growth factor receptor
will recruit a selective array of proteins in response to
ligand activation. For example, in response to
PDGFR activation, Grb2 and SOS translocate as a
complex towards the plasma membrane and the SH2
domain of Grb2 binds to Y716 in the receptor tail.
Once at the membrane, SOS can interact with Ras
and promote GTP exchange and subsequent e¡ector
interaction. Alternatively, Src can bind to the
PDGFR and phosphorylate the adaptor protein
Shc. Once Shc is tyrosine phosphorylated it can
then bind to the SH2 domain of Grb2 thus co-com-
plexing with SOS to allow Ras activation. In addi-
tion, PDGFR activation results in the binding of
p120GAP to Y771, PLC-Q to Y1021, and p85 PI3 ki-
nase to Y740 and Y751 [53]. Thus, both a Ras acti-
vator (SOS) and inhibitor (p120GAP) are simultane-
ously recruited to the receptor and have access to
Ras at the membrane. In this way, there is presum-
ably a transient but controlled regulation of Ras ac-
tivity. The p110 catalytic unit of PI3 kinase is an
e¡ector of Ras. The binding of the p85 subunit of
this enzyme results in the liberation of the p110 sub-
unit to allow its interaction with the e¡ector region
of Ras. Receptor-mediated tyrosine phosphorylation
PLC-Q stimulates the enzyme’s catalytic activity. In
this way, PI(4,5)P2 is hydrolysed to release InsP3 and
DAG which in turn elevates intracellular Ca2 and
activates PKC isoforms [55].
p21 Ras proteins can also be activated by non-
receptor tyrosine kinases such as Src, and Abl. For
example, receptors with no intrinsic tyrosine kinase
activity such as the T Cell antigen receptor (TCR),
and the interleukin receptors for IL-2, IL-3 and IL-5
activate Ras by their interaction with Src family ki-
nases. Members of the Src family include Src, Lck,
Fyn, Lyn, Yes, Fgr, Blk and Yrk. Although mem-
bers of this family can often functionally compensate
for each other, most display a highly selective tissue
distribution [56]. Src family members contain an SH4
domain which allows mirystoylation and membrane
association of the protein. Activation of some Src
family members have been shown to tyrosine phos-
phorylate the adaptor protein Shc [57]. This in turn
results in the recruitment of Grb2 and SOS for Ras
activation.
4.2. G-protein-coupled receptor (GPCR) activation of
Ras
The ability of GPCRs to activate p21 Ras and the
MAPK signalling pathway has been acknowledged
for some time [58^60]. However, it is only recently
that the mechanism involved in the GPCR activation
of Ras has begun to be revealed. A wide range of
receptors which couple to either Gi or Gq subfamilies
have the ability to activate Ras. Most of the work in
this area has been concentrated on thrombin, LPA,
bradykinin, endothelin-1, M1 muscarinic, K1 and K2
adrenoreceptors. Early work which demonstrated the
sensitivity of thrombin- or LPA-mediated Ras acti-
vation to pertussis toxin pretreatment implicated the
involvement of Gi proteins [58]. However, these
GPCR-mediated activations of Ras were also sensi-
tive to genistein, thus indicating that tyrosine kinase
activity was also involved. As more GPCRs were
found to activate Ras, it became apparent that not
all the activation mechanisms involved Gi. Instead,
Gq-coupled receptors were also able to activate Ras
[61,62]. Since the role of Src kinases and adaptor
proteins had been fairly well established by this
time [63,64], various groups began to look for the
involvement of these signalling components in the
GPCR pathways. For example, Src and Fyn were
shown to be activated in response to Gi or Gq acti-
vation [57]. Shc was also shown to become tyrosine
phosphorylated and associate with Grb2 in response
to thrombin or M1 muscarinic receptor activation
[61]. Similarly, the use of Shc-, Grb2-, and SOS-dom-
inant negative mutants demonstrated the functional
requirement for these signalling components in
GPCR activation of the Ras pathway [61,62]. How-
ever, the most signi¢cant ¢nding in this area was the
cloning and characterisation of the focal adhesion
kinase related protein Pyk2 [65]. Pyk2 is a non-re-
ceptor tyrosine kinase which is highly expressed in
the central nervous system. Pyk2 is tyrosine phos-
phorylated and activated in response to elevation of
intracellular Ca2 either by membrane depolarisa-
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tion-induced Ca2 in£ux, Ca2 ionophore treatment
or by bradykinin receptor activation of PLC-L
[66,67]. Pyk2 phosphorylation can be mediated by
both PKC-dependent and PKC-independent mecha-
nisms [62,65,66]. Pyk2 activation leads to the phos-
phorylation of Shc and the formation of a Pyk2/Shc/
Grb2 and/or Pyk2/Src complexes [65,62,67,68]. Tyro-
sine residues in Pyk2 which become phosphorylated
and bind to Src and Grb2 have been identi¢ed [68].
Similarly, the SH2 domains of Src [62,67] Fyn [69]
and Lck [70] have been demonstrated to interact with
tyrosine phosphorylated Pyk2. However, the precise
mechanism by which adaptor proteins and Src ki-
nases interact with each other in this system has yet
to be clari¢ed. There is also evidence for the binding
of Shc to the SH3 domain of Fyn in response to
angiotensin II receptor activation [71]. In addition,
inhibition of this interaction with a Src^Pro peptide,
which competes for SH3 binding, resulted in the sup-
pression of angiotensin II-mediated activation of Ras
[71]. What is emerging, however, is the requirement
for Pyk2, Src kinases, adaptor proteins and SOS in
the activation of Ras by GPCRs [65,62,69,70,72].
Some light has also been shed on the involvement
of Gi and Gq proteins in this process [72]. Studies
with K1 and K2 adrenoreceptors have demonstrated
that both Gi- and Gq-mediated activation of Ras and
the MAPK cascade is blocked when PLC inhibitors
are used. In addition, when LQ G-protein subunits
are sequestered by the expression of a LARK pep-
tide, Gi-mediated activation of Ras is blocked.
Hence, it would appear that the point of convergence
for the Gi and Gq signalling systems is PLC activa-
tion. This in turn would lead to both Ca2 and PKC
activation of Pyk2 (see Fig. 3).
Although the Pyk2 activation pathway to Ras is
falling into place, there is also evidence that there
may be alternative mechanisms operating in Ras-1
¢broblasts [73,74]. In this system, endothelin-1,
LPA and thrombin receptor activation also leads to
MAPK/ Ras activation. However, in response to
GPCR activation, the EGF receptor becomes tyro-
sine phosphorylated (a process which has been
termed ‘transactivation’). When dominant negative
EGF receptors are expressed in this cell line, the
GPCR activation of Ras is blocked. This therefore
suggests that in this system the EGF receptor and
perhaps not Src activation may be coupled to this
pathway [73]. Similarly, other work using dominant
negative Src and Shc expression in this cell line has
led to the conclusion that Src and Shc are not re-
quired for LPA induced MAPK/Ras activation [74].
Instead, a 100 kDa tyrosine phosphorylated protein
has been detected as binding to Grb2 [74]. Thus, if
this protein has the ability to bind to the EGF re-
ceptor, this could be the link to the activation of
Ras. Clearly, the elucidation of the mechanisms by
which GPCRs activate Ras is still incomplete. In
particular, the anomaly that Pyk2 is expressed pre-
dominantly in neuronal tissue indicates a speci¢c role
for this protein in brain function. However, even
though very low levels of Pyk2 have been detected
in non-neuronal tissue, a role for this protein has
been demonstrated in non-neuronal cells by the use
of dominant negative Pyk2 expression [72]. One ex-
planation for this is the possibility that other Pyk2
family members may be expressed in non-neuronal
tissue, but since the cDNAs encoding these proteins
have yet to be cloned, selective probes are not avail-
able for their speci¢c detection.
5. Modulation of intracellular Ca2 by tyrosine
kinases and Ras
Modulation of intracellular Ca2 is important for
the regulation of a wide range of cellular and phys-
iological processes including cell growth, cell prolif-
eration, cell death, vesicle secretion and muscle con-
traction. Rapid intracellular Ca2 concentration
changes are controlled primarily by the regulation
of Ca2 release and/or Ca2 in£ux. Since IP3 is the
major second messenger evoking Ca2 release from
intracellular stores, much work has been undertaken
to investigate the regulatory mechanisms controlling
its production by PLC isoforms. In this way, both
receptor and non-receptor tyrosine kinases have been
implicated in the regulation of intracellular Ca2 re-
lease as a result of their e¡ects on either PLC-L or
PLC-Q. For example, growth factor receptors includ-
ing the PDGF, EGF and NGF receptors are known
to activate PLC-Q directly by tyrosine phosphoryla-
tion [52]. Similarly, the Src family tyrosine kinases
Fyn and Lck have been shown to be activated by
B- or T-cell antigen receptors and thereby play a
role in Ca2 mobilisation mediated by these recep-
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tors in lymphocytes [75^79]. Src also plays a role in
the angiotensin II-mediated phosphorylation and
subsequent activation of PLC-Q in vascular smooth
muscle cells [80]. Similarly, GPCRs which activate Gi
or Gq stimulate PLC-L and therefore IP3-induced
Ca2 release, thus the involvement of GPCRs in
the regulation of tyrosine kinase activity is a conse-
quence of Ca2 elevation.
Tyrosine kinase activity has also been shown to
in£uence the ability of IP3 to release Ca2 from in-
tracellular pools. For example, the type 1 IP3 recep-
tor in T lymphocytes has been shown to be tyrosine
phosphorylated [80] and IP3-mediated Ca2 release
in these cells is regulated by tyrosine kinase activity
[81]. Ras has also been suggested to play a role in
EGF receptor-mediated Ca2 release [82]. It is not
clear, however, at what level Ras is acting,but onco-
genic Ras expression has been demonstrated to in-
crease intracellular IP3 and IP4 levels [83]. Hence,
since IP4 is believed to trigger Ca2 in£ux in a num-
ber of cell types [50,84,85], Ras has the potential to
in£uence Ca2 release via IP3 and in£ux via IP4.
Also, Ca2 elevation resulting from Ca2 release
from intracellular stores can also stimulate Ca2 in-
£ux through Ca2 channels. Intriguingly, Ras and
tyrosine kinases have also been implicated in the reg-
ulation of voltage-dependent Ca2 channels. Micro-
injection studies have demonstrated that both Ras
and Src injection can enhance neuronal Ca2 channel
activity [51]. However, the Src e¡ect was blocked
when dominant negative Ras was co-injected. Thus,
the channel activity is not directly regulated by the
tyrosine kinase, but is instead dependent on the acti-
vation of Ras. Further work which supports a role
for Ras in Ca2 channel activation include the ob-
servations that PDGF receptor activation of Ca2
channels in mesangial cells can be blocked by the
use of anti-Ras antibodies [86], and the expression
of oncogenic Ras in ¢broblasts leads to the activa-
tion of Ca2 channels [87]. The precise mechanism by
which Ras activates Ca2 channels remains to be
determined; however, Src cannot be completely ruled
out as directly activating channels since it has been
shown to physically associate with L-type Ca2 chan-
nels [88]. Thus, Ras and tyrosine kinases clearly have
the ability to in£uence intracellular Ca2 by modu-
lating both release and in£ux processes in a wide
range of cell types (see Fig. 4).
Fig. 4. Modulation of intracellular Ca2 levels by components activating the Ras signalling pathway. Ca2 release from intracellular
pools can be mediated either by growth factor or G-protein-coupled receptors via the activation of PLC isoforms. Ras also enhances
inositol polyphosphate production and can thus play a role in Ca2 release. Ca2 in£ux via voltage-dependent Ca2 channels is also
modulated by Ras and Src kinases. VCC, voltage-dependent Ca2 channel; EGFR, epidermal growth factor receptor.
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6. Questions remaining and future directions
Clearly there are multiple links between intracellu-
lar Ca2 elevation and the regulation of Ras activity.
Since receptor activation of Ras often results in the
activation of one or more isoforms of PLC and/or
the enhancement of Ca2 in£ux, it is di⁄cult to dif-
ferentiate between Ca2-dependent and Ca2-inde-
pendent Ras cellular e¡ects. For many years, tyro-
sine kinase-mediated Ras activation has been
assumed to be the signal for cell growth and prolif-
eration. However, more recently, Ras has been sug-
gested to play a role in the nervous system. In par-
ticular evidence suggests that it may play a role in
neuronal survival [89,90], synaptic transmission and
long-term memory processes [32]. As we learn more
about the function of Ca2-responsive domains, such
as the C2 domain and the IQ motif, we may be able
to understand the Ca2-related function(s) of Ras. In
particular, we may be able to establish if all the sup-
posedly Ras speci¢c GAPs are indeed regulating p21
Ras or if they are each regulating Ras related (but
not p21 Ras) proteins. Also the cellular signals which
activate each GAP are not yet known. For example,
p120GAP is known to be activated by tyrosine kinase
activation and this is not surprising considering it
contains Src homology domains. However, other
Ras GAPs do not contain these domains and their
activation and possibly membrane translocation
mechanisms remain to be established. Also, if the
C2 domains within these GAPs mediate protein^pro-
tein interactions, then the formation of protein com-
plexes could allow these proteins to have cellular
functions which may be distinct from their GTPase
stimulatory activity.
Finally, what about Ras-GRF and GRF2? If Ras-
GRF is important in long-term memory processes,
then what is the function of truncated Ras-GRF
forms and GRF2? Although Ras-GRF and GRF2
share high sequence homology, GRF2 is much more
widely expressed in non-neuronal tissue. Since GRF2
is reported to be Ca2 responsive, then what is
the Ca2 related function of this exchange factor in
cells? Also, are there more Ras-GRF like family
members waiting to be cloned? Clearly the integra-
tion of Ras signalling pathway(s) and Ca2 will be an
exciting and rapidly advancing area for many years
to come.
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